How to Stop a Migraine Headache
1 Pathophysiology & Clinical Overview
Migraine is a primary headache disorder characterized by recurrent, unilateral or bilateral throbbing pain lasting 4–72 hours, often accompanied by nausea, photophobia, phonophobia, and, in approximately 25–30% of cases, aura. The global prevalence exceeds 1 billion individuals, with a 3:1 female-to-male predominance.
The underlying mechanism involves cortical spreading depression (CSD), activation of the trigeminovascular system, and release of calcitonin gene-related peptide (CGRP), substance P, and neurokinin A—resulting in neurogenic inflammation and vasodilation.
Four Phases of Migraine
- Prodrome (Pre-monitory): Occurs hours to days before headache onset. Symptoms include mood changes, neck stiffness, food cravings, yawning, and fatigue.
- Aura: Reversible neurological symptoms (visual, sensory, speech) lasting 5–60 minutes. Present in ~30% of patients.
- Headache: Moderate-to-severe throbbing pain, aggravated by physical activity, with associated nausea and sensory sensitivities.
- Postdrome: Recovery phase characterized by fatigue, cognitive impairment, and scalp allodynia lasting 24–48 hours.
2 Acute Pharmacological Management
Early intervention during the prodrome or mild headache phase significantly improves treatment efficacy. The goal is to achieve pain freedom within 2 hours and restore functional capacity.
2.1 First-Line: NSAIDs & Analgesics
| Medication | Dosing | Evidence Level | Key Considerations |
|---|---|---|---|
| Ibuprofen OTC | 400–800 mg at onset; may repeat every 4–6h (max 2,400 mg/day) | Level A (AHS Guidelines) | Take with food; avoid in peptic ulcer disease, CKD, or anticoagulant therapy |
| Naproxen Sodium OTC | 440–825 mg at onset; may repeat in 4–6h (max 1,375 mg/day) | Level A | Longer half-life than ibuprofen; cardiovascular risk with chronic use |
| Aspirin OTC | 900–1,000 mg at onset | Level A | Contraindicated in children (Reye syndrome), bleeding disorders, and late pregnancy |
| Acetaminophen (Paracetamol) OTC | 1,000 mg at onset; max 3,000 mg/day | Level A | Preferred in patients with GI contraindications to NSAIDs; hepatotoxicity risk at high doses |
2.2 Serotonin 5-HT₁B/₁D Agonists: Triptans
Triptans remain the gold standard for moderate-to-severe migraine attacks. They act via vasoconstriction and inhibition of trigeminal nerve activation and CGRP release.
| Triptan | Formulation | Onset | Special Notes |
|---|---|---|---|
| Sumatriptan Rx | Oral 25–100 mg; SC 4–6 mg; Nasal 5–20 mg | SC: 10–15 min; Oral: 30–60 min | Subcutaneous has fastest onset; most studied triptan |
| Rizatriptan Rx | Oral 5–10 mg; ODT available | ~30 min | Higher efficacy than sumatriptan 100 mg in some RCTs; avoid with propranolol |
| Zolmitriptan Rx | Oral 2.5–5 mg; Nasal 2.5–5 mg | Nasal: ~15 min; Oral: ~45 min | Nasal spray useful for patients with nausea/vomiting |
| Eletriptan Rx | Oral 20–40 mg | ~30 min | Higher 2-hour pain-free rates; CYP3A4 interactions |
⚠️ Triptan Contraindications
- Ischemic coronary artery disease, Prinzmetal angina, or prior MI
- Peripheral vascular disease or uncontrolled hypertension
- Hemiplegic or basilar-type migraine
- Severe hepatic or renal impairment
- Concurrent use of MAO inhibitors or ergot alkaloids
2.3 CGRP Receptor Antagonists (Gepants)
A newer class of acute migraine medications that block CGRP signaling without vasoconstriction—making them safe for patients with cardiovascular contraindications to triptans.
| Agent | Dose | Key Advantage |
|---|---|---|
| Ubrogepant CGRP | 50–100 mg; may repeat after 2h (max 200 mg/day) | No cardiovascular contraindications; no medication-overuse headache risk |
| Rimegepant CGRP | 75 mg ODT | Also FDA-approved for preventive use; favorable safety profile |
| Zavegepant CGRP | 10 mg intranasal | Rapid onset via nasal delivery; useful when oral intake is compromised |
2.4 Ditans
Lasmiditan (50–200 mg oral) is a selective 5-HT₁F agonist without vasoconstrictive properties. Effective for acute treatment but carries a driving restriction due to CNS effects (dizziness, sedation).
2.5 Anti-Emetic Adjuncts
Nausea and gastric stasis impair oral medication absorption. Metoclopramide (10 mg oral/IM/IV) or prochlorperazine (10 mg oral/PR) improve gastric motility and provide antiemetic effects.
3 Non-Pharmacological Acute Interventions
3.1 Environmental Modification
- Photophobia management: Retreat to a dark, quiet room. FL-41 tinted lenses may reduce light sensitivity.
- Thermal therapy: Cold packs applied to the forehead/temples (vasoconstrictive effect) or heat to the posterior neck (muscle relaxation).
- Sensory deprivation: Minimize auditory, olfactory, and visual stimuli.
3.2 Hydration & Electrolyte Balance
Dehydration is a recognized migraine trigger. Oral rehydration with electrolytes (sodium, magnesium) may attenuate attack severity. Intravenous fluids are reserved for intractable cases with vomiting.
3.3 Caffeine
Caffeine (100–200 mg) may enhance analgesic efficacy and improve gastric absorption. However, chronic daily use (>200 mg) increases migraine chronification risk via withdrawal mechanisms.
3.4 Neuromodulation Devices
FDA-cleared non-invasive options:
- Transcranial Magnetic Stimulation (TMS): Single-pulse TMS (sTMS) for aura-associated migraine
- External Trigeminal Nerve Stimulation (eTNS): Cefaly device for acute and preventive use
- Non-Invasive Vagus Nerve Stimulation (nVNS): GammaCore for acute treatment
- Remote Electrical Neuromodulation (REN): Nerivio device worn on the upper arm
4 Preventive Pharmacotherapy
Indications for preventive treatment include ≥4 migraine days/month, significant disability (MIDAS score ≥11), or inadequate response to acute medications.
| Class | Agent | Typical Dose | Adverse Effects |
|---|---|---|---|
| Beta-Blockers | Propranolol, Metoprolol, Timolol | Propranolol: 80–240 mg/day | Fatigue, depression, bradycardia, bronchospasm |
| Anticonvulsants | Topiramate, Valproate | Topiramate: 50–200 mg/day | Cognitive slowing, paresthesia, weight loss (topiramate); teratogenicity (valproate) |
| CGRP mAbs | Erenumab, Fremanezumab, Galcanezumab, Eptinezumab | Monthly or quarterly SC/IV | Injection site reactions; constipation (erenumab); generally well-tolerated |
| OnabotulinumtoxinA | Botox | 155–195 units every 12 weeks (FIXED-DOSE PROTOCOL) | Neck weakness, eyelid ptosis; indicated for chronic migraine (≥15 days/month) |
| Oral Preventives | Amitriptyline, Venlafaxine, Candesartan | Amitriptyline: 10–75 mg qhs; Candesartan: 4–16 mg/day | Anticholinergic effects (amitriptyline); hypotension (candesartan) |
5 Lifestyle & Behavioral Modifications
Sleep Hygiene
- Maintain consistent sleep-wake cycle (±30 min variance)
- Aim for 7–9 hours of sleep
- Treat comorbid sleep disorders (OSA, insomnia)
Nutritional Factors
- Regular meal timing — avoid prolonged fasting
- Identify individual food triggers via headache diary
- Common triggers: aged cheeses, processed meats, MSG, alcohol (especially red wine), artificial sweeteners
Physical Activity
Aerobic exercise (30 minutes, 3–5×/week) reduces migraine frequency and severity. Gradual warm-up is essential, as sudden exertion can trigger attacks.
Stress Management
Cognitive-behavioral therapy (CBT), biofeedback, and mindfulness-based stress reduction (MBSR) demonstrate Level A evidence for migraine prophylaxis.
Supplements with Evidence
| Supplement | Dose | Evidence | Cautions |
|---|---|---|---|
| Magnesium (glycinate/citrate) Supplement | 400–600 mg/day | Level B (AAN) | Diarrhea with oxide form; avoid in severe renal failure |
| Riboflavin (B2) Supplement | 400 mg/day | Level B | Harmless bright yellow urine |
| Coenzyme Q10 Supplement | 100–300 mg/day | Level C | May interact with warfarin |
| Butterbur (PA-free) Supplement | 75–150 mg/day | Level A (historical; now limited due to hepatotoxicity concerns) | Ensure pyrrolizidine alkaloid (PA)-free formulation; liver function monitoring |
6 Red Flags: When to Seek Emergency Evaluation
The "SNOOP" mnemonic guides urgent assessment:
- Systemic symptoms (fever, weight loss, cancer history)
- Neurological deficits or abnormal findings
- Onset sudden ("thunderclap" — peak intensity within 1 minute)
- Older age (>50 years) with new-onset headache
- Pattern change or progressive worsening
- Postural component (worse when supine or with Valsalva)
- Precipitated by exertion or sexual activity
🚨 Emergency Indications
- "Worst headache of life" or thunderclap onset
- Fever with neck stiffness (meningitis concern)
- New focal neurological deficits (weakness, aphasia, visual field loss)
- Altered consciousness, seizures, or papilledema
- Head trauma with progressive headache
- Headache in pregnancy with hypertension/visual changes (preeclampsia/eclampsia)
7 Medication-Overuse Headache (MOH)
Chronic overuse of acute medications paradoxically perpetuates headache. Limits to avoid MOH:
- Triptans, ergots, combination analgesics, opioids: ≤10 days/month
- Simple analgesics (acetaminophen, NSAIDs): ≤15 days/month
- Caffeine-containing medications: ≤10 days/month
MOH treatment requires medication withdrawal (often with bridge therapy such as prednisone or occipital nerve blocks) and initiation of preventive treatment.
8 Clinical Summary & Patient Action Plan
- Recognize prodromal symptoms — act within 15–30 minutes
- Take prescribed acute medication with full glass of water
- Retreat to dark, quiet environment; apply cold compress
- Practice diaphragmatic breathing or progressive muscle relaxation
- If no relief in 2 hours, consider rescue medication or contact provider
Migraine management is multimodal—combining pharmacological acute treatment, preventive strategies, lifestyle optimization, and patient education. Collaboration with a neurologist or headache specialist ensures individualized care, particularly for refractory cases or those with comorbid conditions.
Recent advances in CGRP-targeted therapies and neuromodulation have transformed the therapeutic landscape, offering hope to patients who previously had limited options.
Selected References
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
- American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1-18.
- Ashina M, et al. Migraine: epidemiology and systems of care. Lancet. 2021;397(10283):1485-1495.
- Dodick DW, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3 trial. Lancet Neurology. 2023;22(8):709-717.
- Silberstein SD, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337-1345.
- Schoenen J, et al. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50(2):466-470.
- Diener HC, et al. Efficacy and safety of topiramate in migraine prevention: a pooled analysis. Headache. 2007;47(5):672-681.
Comments